Cogent Biosciences opened lower at $29.01, compared with its previous close of $29.40. In the last trading session, the stock traded between $28.61 and $29.78. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cogent Biosciences is now worth
$ 278.32
Giving a profit of
$ 178.32 (178.32%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.26 (-0.88%)
Day High
$29.78
Day Low
$28.61
Day Open
$29.01
Prev Close
$29.40
Volume
13,54,060
1W Return
-7.42%
1M Return
-2.19%
3M Return
-24.73%
6M Return
-14.55%
1Y Return
-12.81%
Fundamentals
Market Cap ($ Mn)
5,070
PE Ratio
-
PB Ratio
12.72
PEG Ratio
-
ROE
-157.36%
ROCE
-86.86%
EPS (TTM)
$-0.64
Investment Returns
1 Week
-7.42%
1 Month
-2.19%
3 Months
-24.73%
6 Months
-14.55%
9 Months
-21.67%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
9Nov
HC Wainwright raises Cogent Biosciences price target to $56
HC Wainwright maintains a Buy rating on Cogent Biosciences. Price target raised from $55 to $56. Analyst Robert Burns issued the updated recommendation.
3 days ago
21Oct
Cogent Biosciences shares deliver 30.65% annualized return over five years
A $1000 investment made five years ago is now worth $3,787.77. Shares have produced an average annual return of 30.65%. The stock outperformed the market by 19.53% on an annualized basis. Current market capitalization stands at $5.21 billion.
22 days ago
17Sep
Cogent Biosciences stock delivers 30.55% annualized returns over five years
Cogent Biosciences delivered a 30.55% average annual return over five years. Stock outperformed the broader market by 18.64% on an annualized basis. Current market capitalization stands at $5.86 billion. A $100 investment five years ago grew to $378.75 based on current pricing.
1mo ago
16Sep
Wedbush maintains $55 target, Outperform rating on Cogent Biosciences
Wedbush reiterates Outperform rating on Cogent Biosciences (NASDAQ: COGT). Price target remains unchanged at $55 per share. Analyst David Nierengarten issued the updated note.
1mo ago
3Sep
Cogent Biosciences signs bezuclastinib supply deal with Hovione
Cogent Biosciences signed a commercial supply agreement with Hovione on September 1, 2026. The deal covers manufacturing of bezuclastinib spray-dried dispersion and tablets. Cogent must buy minimum percentages of requirements, which decrease over time. Initial term is five years with automatic two-year renewals. Either party can terminate for breach, insolvency, or regulatory changes.
2mo ago
1Sep
Cogent Biosciences $100 investment worth $415.68 after 33.55% annualized return
Cogent Biosciences posted a 33.55% annualized return over five years. Stock outperformed the broader market by 22.44% annually. A $100 investment from five years ago is now worth $415.68. Current market capitalization stands at $6.12 billion. Share price was recorded at $35.25 at the time of writing.
